Cervical cancer is the second most common malignancy in women worldwide. To improve prognosis and predict treatment response, clinical stratification is required.
Cervical cancer exhibits clinical heterogeneity, albeit HPV is recognised as the major etiological cause of carcinogenesis. Preventive vaccination is expected to impact incidence rates in more than 20 years from now, so in the meantime, there is an imminent need to improve treatment of cervical cancer where no prognostic and predictive biomarkers .
Further details: From molecular profiling to clinical stratification